💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Marksans Pharma Limited is an India-based company, which is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. It operates two manufacturing facilities in Goa and maintains two research and development centers, one…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, steadily growing business, priced for perfection.
Marksans Pharma is scored on the pharma / healthcare framework. It keeps a healthy 13.8% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 1.09×). Free cash flow is worth about 1.5% of its market value.
Over the last 3 years revenue compounded at 17%/yr and profit at 17%/yr. Book value itself has compounded 20%/yr — the hallmark of a genuine compounder. Return on equity is a healthy 16.8%. In the latest quarter profit grew 7% versus the prior quarter.
At 33× earnings, the stock sits at the 81st percentile of its own 3.6-year range — the expensive end of where it has historically traded. Today's price implies ~12%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 24.35 | — | — |
| P/B | 4.13 | 4.1 | worse |
| EV/EBITDA | 15.44 | 19.33 | better |
| ROE | 16.8 | — | — |
| ROCE | 20.46 | 14.41 | better |
| ROA | 12.97 | — | — |
| Quick Ratio | 3.32 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 17% CAGR over 3 years — steady double-digit compounder. Growth is decelerating — latest year grew slower than the year before.
Net profit has risen every year — the hallmark of a compounder.
Operating margins have been stable around 18% — no major structural shift.
ROE at 14% — a respectable return on shareholder capital. Low variance across years — a predictable business that earns steadily on its equity base.
EPS has grown every year — each share earns more than the last, consistently. Profit grew faster than EPS (17% vs 13%) — share dilution is eroding per-share value. 13% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Run-rate stepping up — recent quarters average 16% above earlier ones.
Quarterly net margins are expanding (13% → 18%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 43.9% — dispersed ownership; institutional flows drive the stock. FIIs have accumulated for 3 straight quarters — sustained foreign institutional conviction.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.